Telix Pharmaceuticals (NasdaqGS:TLX) FY Conference Transcript

Telix Pharmaceuticals FY Conference Summary Company Overview - Company: Telix Pharmaceuticals (NasdaqGS:TLX) - Focus: Development of therapeutics pipeline, particularly in the radiopharmaceutical space - Key Leadership: Group CEO Christian Behrenbruch Core Industry Insights - Industry: Radiopharmaceuticals - Market Dynamics: Increased investment in in-house innovation and development of therapeutics pipeline - Competition: Notable competitors include Novartis, Lantheus, and others in the radiopharmaceutical market Financial Performance - 2025 Revenue: Record year with AUD 804 million, a 56% year-on-year increase - 2026 Guidance: Expected revenue in the range of $950-$970 million, excluding unapproved products [5][6] Product Pipeline and Strategy - Therapeutics Pipeline: Three programs in late-stage clinical trials, with a focus on growing core business and launching new products - Key Products: - Zircaix and Pixclara: Expected to be refiled in 2026, significant revenue streams anticipated [6][32] - Gozellix: Launched with a new clinical utility and different distribution profile, expected to drive average selling price (ASP) higher [15][16] - RLS Acquisition: Successful acquisition contributing to revenue and expected to grow with third-party contracts [6][25] Market Expansion and International Strategy - International Expansion: Filed Pixclara in Europe and NDA in China, with ongoing studies in Japan [28][29] - Market Opportunities: Potential to double the size of the prostate cancer imaging market in the U.S. through ongoing studies [29][30] Clinical Trials and Data - ProstACT Global Trial: U.S. requirement met, progressing to randomization ex-U.S. with a focus on safety and dosimetry [39][41] - TLX250 and TLX090: Expected updates and interim analyses in 2026, with potential for early approval based on positive data [75][82] Key Challenges and Considerations - Regulatory Hurdles: Previous CRLs for Pixclara and Zircaix have delayed timelines but are now being addressed [32][34] - Market Perception: Company viewed as a pro rata of Lantheus, with a need to better communicate the value of its therapy pipeline [84][85] Conclusion - Outlook: Positive growth anticipated in 2026 with a strong focus on therapeutics and international expansion, despite regulatory challenges and market competition [6][84]